TY - JOUR T1 - Vaccination efforts in Brazil: scenarios and perspectives under a mathematical modeling approach JF - medRxiv DO - 10.1101/2021.02.22.21252208 SP - 2021.02.22.21252208 AU - Thomas Nogueira Vilches AU - Felipe Alves Rubio AU - Rafael Augusto Forti Perroni AU - Gabriel Berg de Almeida AU - Carlos Magno Castelo Branco Fortaleza AU - Cláudia Pio Ferreira Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252208.abstract N2 - An agent-based model is proposed to access the impact of vaccination strategies to halt the COVID-19 spread. The model is parameterized using data from São Paulo State, Brazil. It was considered the two vaccines that are already approved for emergency use in Brazil, the CoronaVac vaccine developed by the Chinese bio-pharmaceutical company Sinovac and the Oxford-AstraZeneca vaccine (ChadOx1) developed by Oxford University and the British laboratory AstraZeneca. Both of them are two-dose schemes, but the efficacy and the interval between doses are different. We found that even in the worst scenario, in which the vaccine does not prevent infection either severe symptoms, the number of deaths decreases from 122 to 99 for CoronaVac application and to 80 for ChadOx1 administration. The same patterns have been seen in hospitalizations. Nevertheless, we show that when a low risk perception occurs, the reduction values decrease between 2% to 4%. Moreover, the increase of disease prevalence also jeopardizes immunization, showing the importance of the mitigation measures maintenance. On the other hand, doubling the vaccination rate would be able to significantly decrease the disease outcomes, reducing deaths by up to 74.4%. In conclusion, vaccination, along with non-pharmaceutical measures, is key to the control of COVID-19 in Brazil.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTNV thanks to S&atildeo Paulo Research Foundation (grant 2018/24811-1); FAR and RFP thank to Coordena&ccedil&atildeo de Aperfei&ccediloamento de Pessoal de N&iacutevel Superior - CAPES (grant #001). The research of CPF is supported by grants ##2019/22157-5 and 2020/10964-0, S&atildeo Paulo Research Foundation (FAPESP) and by grant #302984/2020-8, National Council for Scientific and Technological Development (CNPq).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:this work is exempt from ethical approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data is publicly available, including the source code of the model. ER -